AR040472A1 - Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit - Google Patents
Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kitInfo
- Publication number
- AR040472A1 AR040472A1 AR20030102321A ARP030102321A AR040472A1 AR 040472 A1 AR040472 A1 AR 040472A1 AR 20030102321 A AR20030102321 A AR 20030102321A AR P030102321 A ARP030102321 A AR P030102321A AR 040472 A1 AR040472 A1 AR 040472A1
- Authority
- AR
- Argentina
- Prior art keywords
- atoms
- mono
- hal
- con
- coor2
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000004429 atom Chemical group 0.000 abstract 10
- 229920006395 saturated elastomer Polymers 0.000 abstract 5
- 101150047265 COR2 gene Proteins 0.000 abstract 4
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 abstract 1
- 101000582254 Homo sapiens Nuclear receptor corepressor 2 Proteins 0.000 abstract 1
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10229070A DE10229070A1 (de) | 2002-06-28 | 2002-06-28 | Phenylderivate 5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040472A1 true AR040472A1 (es) | 2005-04-06 |
Family
ID=29723536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102321A AR040472A1 (es) | 2002-06-28 | 2003-06-27 | Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050203127A1 (https=) |
| EP (2) | EP1679073A1 (https=) |
| JP (1) | JP2005535630A (https=) |
| AR (1) | AR040472A1 (https=) |
| AU (1) | AU2003238475A1 (https=) |
| CA (1) | CA2491271A1 (https=) |
| DE (1) | DE10229070A1 (https=) |
| WO (1) | WO2004002477A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2416384A1 (en) * | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
| US20070004736A1 (en) * | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| DE102004051277A1 (de) * | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| WO2006047415A2 (en) | 2004-10-26 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Factor xa compounds |
| DE102005038947A1 (de) * | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| DE102005045115A1 (de) * | 2005-09-21 | 2007-04-05 | Siemens Ag | Verfahren und Vorrichtung zum Betrieb eines Kommunikationsendgeräts |
| CA2739488A1 (en) | 2008-10-15 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Fused heteroaryl diamide compounds useful as mmp-13 inhibitors |
| CA2738929A1 (en) | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
| CN102918034B (zh) | 2010-03-30 | 2015-06-03 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| LT2968297T (lt) | 2013-03-15 | 2019-01-10 | Verseon Corporation | Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| SG10202103278TA (en) | 2013-10-14 | 2021-04-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| KR102736869B1 (ko) | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| CN106687445A (zh) | 2014-09-17 | 2017-05-17 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物 |
| RU2017131562A (ru) | 2015-02-27 | 2019-03-27 | Версеон Корпорейшн | Замещенные пиразольные соединения как ингибиторы сериновых протеаз |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU730224B2 (en) * | 1996-12-23 | 2001-03-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| ZA985247B (en) * | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| SK174699A3 (en) * | 1997-06-19 | 2000-08-14 | Du Pont Pharm Co | Inhibitors of factor xa with a neutral p1 specificity group |
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
-
2002
- 2002-06-28 DE DE10229070A patent/DE10229070A1/de not_active Withdrawn
-
2003
- 2003-06-05 EP EP06000157A patent/EP1679073A1/de not_active Withdrawn
- 2003-06-05 CA CA002491271A patent/CA2491271A1/en not_active Abandoned
- 2003-06-05 US US10/519,356 patent/US20050203127A1/en not_active Abandoned
- 2003-06-05 EP EP03732540A patent/EP1517685A1/de not_active Withdrawn
- 2003-06-05 AU AU2003238475A patent/AU2003238475A1/en not_active Abandoned
- 2003-06-05 JP JP2004516575A patent/JP2005535630A/ja active Pending
- 2003-06-05 WO PCT/EP2003/005898 patent/WO2004002477A1/de not_active Ceased
- 2003-06-27 AR AR20030102321A patent/AR040472A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2491271A1 (en) | 2004-01-08 |
| DE10229070A1 (de) | 2004-01-15 |
| WO2004002477A8 (de) | 2004-04-15 |
| JP2005535630A (ja) | 2005-11-24 |
| US20050203127A1 (en) | 2005-09-15 |
| AU2003238475A1 (en) | 2004-01-19 |
| WO2004002477A1 (de) | 2004-01-08 |
| EP1679073A1 (de) | 2006-07-12 |
| EP1517685A1 (de) | 2005-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040472A1 (es) | Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit | |
| AR041024A1 (es) | Derivados de benzimidazol como inhibidores del factor de coagulacion xa | |
| GT200600398A (es) | Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso | |
| NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
| AR049502A1 (es) | Derivados de carbonilo heterociclicos | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| ECSP024364A (es) | Antagonistas receptores de adenosina a2a | |
| PE20060775A1 (es) | Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa | |
| AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| PE20241129A1 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| CL2004000720A1 (es) | COMPUESTOS DERIVADOS DE PIRAZOLIDINA-1,2-DICARBOXILDIFENILAMIDA, INHIBIDORES DE LOS FACTORES DE COAGULACION Xa, VIIa; PROCESO DE PREPARACION; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; KIT FARMACEUTICO; Y SU USO PARA TRATAR TROMBOSIS, INFAR | |
| PE20040458A1 (es) | Piridinas sustituidas con actividad anti-angiogenica | |
| AR037754A1 (es) | Herbicidas | |
| DE60212836D1 (de) | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten | |
| DE60217114D1 (de) | Verbrückte bizyklische serinproteaseinhibitoren | |
| AR065937A2 (es) | Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa | |
| EA201890903A9 (ru) | Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
| AR063099A1 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| UY29246A1 (es) | Nuevos compuestos | |
| EA200401167A1 (ru) | Производные тропана в качестве модуляторов ccr5 | |
| MX2024007904A (es) | Compuestos y uso de estos como inhibidores de hdac6. | |
| PE20090110A1 (es) | Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |